Live Webinar by MedAxiom Features Best Practices Using Daxor’s Blood Volume Analysis (BVA-100®) to Improve Heart Failure Outcomes and Reduce Costs
November 10, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces Daxor’s BVA-100 diagnostic will be...
Newly Published Study Demonstrates Significant Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Evaluation of Heart Failure
November 03, 2022 08:00 ET
|
Daxor Corporation
Study Highlighted That Only The BVA-100 Accurately Measures Volume Derangements Compared to Commonly Used Surrogates Oak Ridge, TN, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq:...
Daxor Corporation to Exhibit at American Heart Association’s Scientific Sessions 2022
October 31, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be attending the American Heart...
Expert Panel Calls for Use of Blood Volume Measurement to Assess Heart Failure Patients at Key Scientific Meeting
October 05, 2022 08:30 ET
|
Daxor Corporation
Evidence Presented Utilizing Daxor’s BVA-100® Blood Volume Test Oak Ridge, TN, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
DAXOR CORPORATION TO EXHIBIT AND PRESENT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE FALL’22 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
October 04, 2022 08:30 ET
|
Daxor Corporation
The Premier Event For The Cardiovascular Industry's Leading Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically Improve Their Business and...
Study Data from Mayo Clinic on Heart Failure Treatment Effectiveness Utilizing Daxor BVA-100 Presented at Key Scientific Meeting
October 04, 2022 08:00 ET
|
Daxor Corporation
Traditional Care: More than 50% Discharged From Hospital With Suboptimal Treatment Oak Ridge, TN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood...
New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
October 03, 2022 09:00 ET
|
Daxor Corporation
Patients Receiving BVA Stayed 2.5 Fewer Days in Hospital Resulting in Reduced Costs of Care Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation, the global leader in blood volume...
New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care
October 03, 2022 08:40 ET
|
Daxor Corporation
Patient One-Year Mortality Rate 5.6% with BVA-Guided Care Compared to 36.8% in Control Group - Data Presented at Key Scientific Meeting Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor...
New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures
October 03, 2022 08:00 ET
|
Daxor Corporation
Presented at Key Scientific Society Meeting -Commonly Used Pressure Measures for Volume Assessment Proven Not Equivalent to BVA Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America
September 26, 2022 08:00 ET
|
Daxor Corporation
Compelling New Patient Outcome Data to be Presented Oak Ridge, TN, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology,...